论文部分内容阅读
目的:观察脂微球前列腺素E1联合氯沙坦对糖尿病肾病(DN)患者24 h蛋白尿和肾功能的影响。方法:63例2型糖尿病肾病患者随机分为对照组和治疗组,两组患者均给予适量运动、饮食控制、降糖、降脂等常规治疗,对照组在常规治疗基础上给予氯沙坦治疗,而治疗组则同时给予脂微球前列腺素E1和氯沙坦,疗程共12周,分别观察治疗前后两组患者空腹血糖、肾功能及24 h尿蛋白的变化。结果:治疗12周后,两组患者空腹血糖控制良好,治疗组患者肾功能较治疗前明显改善(P<0.05),且尿白蛋白排泄率较对照组明显下降,分别为(322.12±50.21)mL/min和(276.57±38.12)mL/min,两者间的差异具有显著性意义。结论:脂微球前列腺素E1联合氯沙坦能明显改善糖尿病肾病患者肾脏功能,减少24 h尿蛋白。
Objective: To observe the effect of lipid microsphere prostaglandin E1 combined with losartan on proteinuria and renal function in 24 h patients with diabetic nephropathy (DN). Methods: Sixty-three patients with type 2 diabetic nephropathy were randomly divided into control group and treatment group. Both groups were given regular exercise, diet control, hypoglycemic, lipid-lowering and other conventional treatment. The control group received losartan on the basis of routine treatment , While the treatment group was given both lipid microspheres prostaglandin E1 and losartan, a total of 12 weeks treatment were observed before and after treatment in patients with fasting blood glucose, renal function and 24 h urinary protein changes. Results: After 12 weeks of treatment, the fasting blood glucose was well controlled in both groups. The renal function of the treatment group was significantly improved (P <0.05) and the urinary albumin excretion rate was significantly lower than that of the control group (322.12 ± 50.21, mL / min and (276.57 ± 38.12) mL / min, respectively. There was a significant difference between the two groups. Conclusions: Lipopeptide prostaglandin E1 combined with losartan can significantly improve renal function in patients with diabetic nephropathy and decrease urinary protein in 24 hours.